GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.